Samsung Biologics Enters Preclinical Research with Launch of Organoid Drug Screening
The new service will enable precision screening to predict patient responses, streamline preclinical development processes, and accelerate timelines for investigational new drug (IND) filings.
Samsung Biologics, a South Korea-based contract development and manufacturing organization (CDMO), has launched a new organoid-based drug screening service under the name Samsung Organoids.
The announcement was made on Tuesday, June 17, 2025, at the company’s Incheon headquarters.
Samsung Organoids is designed to aid pharmaceutical clients in early-stage drug discovery and development by offering three-dimensional cell culture systems that closely mimic human organs.
These organoids enable clinically relevant insights into specific drug responses and are increasingly seen as effective research models for biomarker discovery and drug efficacy prediction.
The new service will enable precision screening to predict patient responses, streamline preclinical development processes, and accelerate timelines for investigational new drug (IND) filings.
By integrating advanced data analytics, Samsung Organoids offers multi-modal insights into the characteristics and mechanisms of drug candidates, supporting lead selection and clinical planning.
With this launch, Samsung Biologics extends its scope beyond manufacturing to include preclinical research. The company now offers a wider suite of services that cover the full drug development life cycle—from target discovery and preclinical development to clinical trial planning.
“The latest service launch reflects our unwavering commitment to driving innovation by improving drug success rates and creating new possibilities in personalized medicine,” said John Rim, CEO and president of Samsung Biologics. “The addition of research services is a significant move for us to create added value for clients by supporting the drug life cycle from start to finish with thorough therapeutic analysis.”
The company stated that the move aims to address key challenges in the early drug development phase by providing data-backed solutions to improve clinical outcomes.
Stay tuned for more such updates on Digital Health News
